End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
57.16 CNY | -0.24% | -0.61% | -16.15% |
04-29 | Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 62 Yuan From 87 Yuan, Keeps at Hold | MT |
04-26 | Yunnan Botanee Bio-Technology Group Co.LTD Proposes Final Dividend for 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.15% | 3.32B | C+ | ||
-2.16% | 250B | B- | ||
+12.81% | 19.77B | B+ | ||
0.00% | 17.89B | - | - | |
+0.38% | 11.09B | A- | ||
+16.34% | 7.75B | B+ | ||
+10.15% | 5.97B | B | ||
+1.12% | 4.52B | B+ | ||
-17.29% | 3.8B | C- | ||
-5.56% | 3.45B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300957 Stock
- Ratings Yunnan Botanee Bio-Technology Group Co.LTD